Company / SG&A Expense
HERBALIFE LTD. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.7B
FY2025
5-year range
$1.7B / $2.0B
FY2021-FY2025
Trend
-11.3%
vs FY2024
Sector context
#33 of 158
Health Care
What the data says
HERBALIFE LTD.'s sg&a expense of $1.7B is higher than 79% of companies in the Health Care sector (FY2025). SG&A Expense has fluctuated over the past 10 years, ranging from $1.7B in FY2025 to $2.0B in FY2023.
Based on SEC 10-K filings.
$1.7B in FY2025 with a 5-year CAGR of -3.2%. Top quartile in the Health Care sector.
Improved from $2.0B to $1.7B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -2.8%
- 5-Year CAGR
- -3.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 158This company $1.7B Sector average $175.9B
▼
-99.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -3.2%, indicating a declining trend.
- In FY2025, sg&a expense decreased 11.3% year-over-year.
- Ranks #33 out of 158 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.7B | -11.3% |
| FY2024 | $1.9B | -6.8% |
| FY2023 | $2.0B | +11.1% |
| FY2022 | $1.8B | -6.7% |
| FY2021 | $1.9B | -0.8% |
| FY2020 | $2.0B | +11.2% |
| FY2019 | $1.8B | -10.6% |
| FY2018 | $2.0B | +10.2% |
| FY2017 | $1.8B | -10.4% |
| FY2016 | $2.0B | +22.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026